Upadacitinib in Perianal Crohn’s Disease: CGH | May 2026

Introduction

Perianal Crohn’s disease (pCD) remains one of the most challenging manifestations of inflammatory bowel disease, often associated with fistulas, recurrent infections, impaired quality of life, and repeated surgeries. Although anti-TNF agents have been the cornerstone of therapy, many patients experience incomplete response or treatment failure. Upadacitinib (UPA), a selective JAK1 inhibitor, has shown promise in clinical trials, but real-world evidence in perianal disease has been limited.

Problem Statement

Management of perianal Crohn’s disease remains difficult because:

Complex fistulas frequently persist despite biologic therapy

Radiologic healing is difficult to achieve

Long-standing disease often becomes refractory

Real-world effectiveness data for newer agents like UPA are scarce

The key question was:

Can upadacitinib improve both clinical and radiologic outcomes in real-world perianal Crohn’s disease?

Summary

This multicenter North American study evaluated 125 patients with active perianal Crohn’s disease treated with upadacitinib. Most patients had severe disease, with nearly half having complex fistulas and over 75% previously exposed to anti-TNF therapy.

The study demonstrated meaningful clinical improvement:

Nearly 46% achieved clinical response

Around 39% achieved clinical remission

MRI improvement was seen in over half of patients

Complete radiologic healing occurred in approximately 11%

Hospitalization and surgery rates were relatively low during follow-up.

Importantly, outcomes were significantly better in:

Anti-TNF–naïve patients

Patients with shorter disease duration

Prior anti-TNF exposure predicted lower response rates, suggesting earlier introduction of UPA may yield better outcomes.

Overall, this real-world study supports upadacitinib as a promising therapeutic option for perianal Crohn’s disease, particularly when used earlier in the disease course before multiple biologic failures occur.